FDA Issues New Potassium Iodide Dosage Guidelines

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 3
Volume 11
Issue 3

ROCKVILLE, Maryland-The FDA has issued new recommendations for administering potassium iodide to reduce the risk of thyroid cancer in children and adults in emergencies involving the release of radioactive iodine into the environment.

ROCKVILLE, Maryland—The FDA has issued new recommendations for administering potassium iodide to reduce the risk of thyroid cancer in children and adults in emergencies involving the release of radioactive iodine into the environment.

The new FDA guideline recommends a standard daily dose of 16 mg of potassium iodide for infants less than 1 month old; 32 mg for children 1 month to 3 years; 65 mg for those between ages 3 and 18 years; and 130 mg for adults, including pregnant and lactating women, and adolescents who weigh more than 150 pounds.

FDA adds that, as a general rule, daily dosing should continue until the risk of exposure has passed and/or until other protective measures are successfully in place.

Related Videos
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.